TYO:4507
When the world needs a pill to fight a virus, a Japanese company is increasingly part of the answer. Shionogi has made antivirals its strategic specialty — from a flu drug taken in a single dose to one of the first oral pills shown to prevent COVID-19 after exposure. It is quietly positioning itself for the age of infectious-disease threats.
An antiviral specialist
Founded in 1878 in Osaka, Shionogi is a mid-sized pharmaceutical company that made a deliberate strategic bet on infectious diseases. Its flu drug Xofluza (baloxavir) treats influenza with a single oral dose, and during the pandemic it developed Xocova/ensitrelvir, an oral COVID-19 antiviral. In 2026 ensitrelvir advanced as the first oral therapy for post-exposure prevention of COVID-19 — taken to stop infection after contact with a case — a genuinely novel approach backed by major clinical evidence.
Built for the next outbreak
Beyond flu and COVID, Shionogi has deep roots in HIV (through its stake in ViiV Healthcare) and antibiotics, and it positions infectious-disease readiness as a core mission — a rare focus as many large drugmakers retreated from antivirals and antibiotics due to weak economics. That commitment makes Shionogi strategically important to global pandemic preparedness, and gives it a differentiated pipeline.
Why it matters for global partners and investors
- Investors get exposure to a focused, R&D-driven drugmaker with a differentiated antiviral franchise and pandemic-preparedness relevance.
- Health systems and partners value antiviral and antibiotic developers as a strategic resource against recurring infectious threats.
- The watch item is regulatory progress and commercial uptake of ensitrelvir outside Japan, and the durability of antiviral demand between outbreaks.
Frequently asked questions
What is Shionogi known for?
Shionogi is a Japanese pharmaceutical company specialising in infectious diseases. It makes the single-dose flu drug Xofluza and the COVID-19 antiviral Xocova/ensitrelvir, and has roots in HIV and antibiotics.
What is special about its COVID drug?
In 2026 its antiviral ensitrelvir advanced as the first oral therapy for preventing COVID-19 after exposure — taken to stop infection following contact with a case — a novel post-exposure-prevention approach.
Why does Shionogi matter?
It is one of the few drugmakers strategically committed to antivirals and antibiotics, making it important to global readiness for infectious-disease threats.
Looking to partner with, or invest in, a Japanese pharmaceutical innovator? Contact Japonity — we connect international businesses with Japan’s best companies, products, and technologies.
Interested in Japanese business opportunities?
Whether you're looking for technology partners, engineering talent, or market insights — we can help connect you with the right Japanese organizations.
Get in Touch →
